Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +1.05%58 3-Year Book Growth Rate is -8.80% as of Jun. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €7.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,848 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 87.34% on this metric.
During the past 12 months, InnoCan Pharma's average Book Value per Share Growth Rate was 17.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of InnoCan Pharma was 240.20% per year. The lowest was -18.40% per year. And the median was 15.10% per year.
InnoCan Pharma (FRA:IP40) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
InnoCan Pharma 3-Year Book Growth Rate Related Terms
FRA:IP40 vs PG, CL, EL: 3-Year Book Growth Rate Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma 3-Year Book Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's 3-Year Book Growth Rate falls into.
InnoCan Pharma 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -8.80% mean?
InnoCan Pharma (FRA:IP40) has a 3-Year Book Growth Rate of -8.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1614 out of 1848 companies in the Consumer Packaged Goods industry, placing it in the top 87.3%.
Is InnoCan Pharma's 3-Year Book Growth Rate too high?
InnoCan Pharma's current 3-Year Book Growth Rate is -8.80%. Based on the distribution chart, InnoCan Pharma ranks #1614 out of 1848 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's 3-Year Book Growth Rate compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1614 out of 1848 companies for 3-Year Book Growth Rate. This places InnoCan Pharma in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Consumer Packaged Goods company?
The median 3-Year Book Growth Rate among Consumer Packaged Goods companies is 4.70, based on 1,848 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median 3-Year Book Growth Rate is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current 3-Year Book Growth Rate is -8.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.11, compared to a current price of €1.44 — trading 79.7% below its estimated fair value. The current 3-Year Book Growth Rate is -8.80%. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current 3-Year Book Growth Rate is -8.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.44 is trading 79.7% below its estimated GF Value™ of €7.11.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
3-Year Book Growth Rate: -8.80%
GF Value™: €7.11 vs. price of €1.44 (79.7% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
